The company relies on its own R&D team to build an efficient drug development technology platform and develop the innovative drug products with completely independent Intellectual Property Rights to meet the urgent clinical needs in the field of Metabolic and Immunology Diseases. The company is currently building Seven technology platforms, including AI pharmaceuticals, Nucleic Acid Drug Development, Nucleic Acid Targeted Delivery, Cell Drug Development, Macromolecule Drug Development, and Novel Formulation Development. All pipelines and platforms are independently developed, and a number of patents have been applied. The company will rely on its own innovative technology platform, guided by clinical needs, adhere to the patient-centered R&D concept, and promote the improvement of the quality and value of innovative drugs in China.